With David Fox, Marie Vodicka
On 9 May 2011, the Food and Drug Administration (FDA) issued a request for comments on the agency's proposed options for a user fee program for biosimilar and interchangeable biological applications for fiscal years 2013-17, which is required by the Biologics Price Competition and Innovation Act of 2009 (BPCIA).